Metastatic clear cell RCC first-line treatment selection

Authored by Toni Choueiri, published on 2026-05-28 09:15:02.0

Algorithm for selection of first-line treatment for patients with metastatic clear cell RCC (mccRCC). The National Comprehensive Cancer Network, European Association of Urology, and European Society of Medical Oncology guidelines recommend alternative approaches. axi = axitinib; cabo = cabozantinib; IMDC = International Metastatic RCC DatabaseConsortium; ipi = ipilimumab; lenva = lenvatinib ; Nivo = nivolumab; Pembro = pembrolizumab; RCC = renal cell carcinoma; SBRT = stereotactic body radiotherapy; TKI = tyrosine kinase inhibitor.Multidisciplinary tumor board discussion should include, but not be limited to, patient preferences and goals, review of images and pathology, need for referral to a high-volume center, potential inclusion in clinical trials, and requirements for additional supportive care interventions.First and Second-line Treatments in Metastatic Renal Cell Carcinoma, European Urology, Volume 87, Issue 2, 2025, Pages 143-154, https://doi.org/10.1016/j.eururo.2024.10.019.

  1. Metastatic clear cell RCC
    High-level first-line treatment selection for metastatic clear cell RCC is best supported by major guidelines and contemporary syntheses that integrate the pivotal IO/IO and IO/TKI randomized trials.
    • Multidisciplinary tumor board discussion*
      • Oligometastatic RCC
        The decision to consider local therapies/observation and selective surgery in oligometastatic disease is addressed in major guidelines, though the evidence base is more heterogeneous than for systemic therapy.
        • Yes
          • Observation, SBRT, metastasectomy +/- pembrolizumab (<1y from nephrectomy) In select cases: cytoreductive nephrectomy
            Observation and local therapy (SBRT/metastasectomy) for selected oligometastatic patients are guideline-supported Cytoreductive nephrectomy is supported by RCTs from the targeted-therapy era with evolving applicability in the IO era The specific suggestion of adding pembrolizumab based on time from nephrectomy is less directly supported by definitive randomized evidence in the oligometastatic setting and should be considered exploratory/individualized.
        • No
          • Sarcomatoid features
            • Yes
              • Nivo+ipi
            • No
              • IMDC risk group
                • Favorable risk
                  • Pembro+axi, nivo+cabo or pembro+lenva In select cases: nivo+ipi or TKI monotherapy
                • Intermediate and poor risk
                  • Need for rapid disease-control
                    • No
                      • Physician’s preference: nivo+ipi, pembro+axi, nivo+cabo or pembro+lenva In select cases: TKI monotherapy
                    • Yes
                      • Pembro+axi, nivo+cabo or pembro+lenva In select cases: nivo+ipi or TKI monotherapy
tosprivacyFirst and Second-line Treatments in Metastatic Renal Cell Carcinoma